Cirrhosis is permanent scarring of the liver that develops after years of repeated injury, making it harder for the liver to do its job. In its earliest stage it often causes no symptoms, which is why many people do not know they have it until the disease is fairly advanced. Cirrhosis is common in the United States, most often caused by chronic heavy alcohol use, fatty liver disease linked to metabolic conditions, or chronic viral hepatitis, but a diagnosis is not automatically a worst case: treating the underlying cause can slow or halt progression, and earlier liver damage can sometimes be reversed. This guide explains what cirrhosis is, its symptoms, causes, how it is diagnosed, the treatments available, and the latest research.
What is cirrhosis?
Cirrhosis is advanced, permanent scarring of the liver. Ongoing injury from any cause triggers repeated cycles of damage and repair, and over years that process lays down scar tissue that replaces healthy liver tissue. As scarring spreads, it distorts the liver’s internal structure, blocks normal blood flow, and reduces the working tissue left to filter the blood and produce proteins the body needs to clot and heal.
Doctors describe cirrhosis in two broad stages that shape almost everything else in this guide. In compensated cirrhosis, enough healthy liver tissue remains to keep up with the body’s needs, and many people have few or no symptoms for years. In decompensated cirrhosis, the liver can no longer keep up, and complications such as fluid buildup in the abdomen, bleeding, jaundice, or confusion appear. Chronic liver disease and cirrhosis caused more than 52,000 US deaths in 2024, the ninth leading cause of death nationally, underscoring why the shift from compensated to decompensated disease is tracked so closely.
Symptoms of cirrhosis
In compensated cirrhosis, symptoms are often minimal or absent, a major reason the disease can progress unnoticed for years. When signs do appear, they tend to be general: fatigue, loss of appetite, easy bruising or bleeding, itchy skin, and mild jaundice, a yellowing of the skin and eyes. Some people develop spider angiomas, small clusters of visible blood vessels on the skin, or palmar erythema, a reddening of the palms.
Decompensated cirrhosis brings more serious problems: ascites, a buildup of fluid in the abdomen, with swelling in the legs; bleeding from enlarged, fragile veins in the esophagus called varices; confusion or personality changes from hepatic encephalopathy; and muscle wasting. Because these symptoms mark a turning point, they usually prompt closer monitoring and a conversation about liver transplant evaluation.
What causes cirrhosis and its risk factors
Cirrhosis develops when something injures the liver repeatedly over years, and the organ’s own repair process lays down scar tissue faster than the body can clear it. In the United States, the leading causes are long-term heavy alcohol use, metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic viral hepatitis. In 2023, a multi-society consensus renamed NAFLD and NASH to MASLD and MASH to better reflect cardiometabolic drivers such as obesity, diabetes, and insulin resistance, rather than defining the disease by what it is not. MASH, the more aggressive form of MASLD in which fat buildup causes liver inflammation and damage, is now one of the fastest-growing causes of cirrhosis.
Recognizing a hepatitis B infection and a hepatitis C infection as major causes worldwide and in the US matters, since early antiviral treatment can prevent or slow progression to cirrhosis. Less common causes include autoimmune hepatitis, hereditary hemochromatosis (inherited iron overload), primary biliary cholangitis, and rarer genetic conditions such as alpha-1 antitrypsin deficiency. Risk rises with the amount and duration of alcohol use, excess body weight, type 2 diabetes, and untreated viral hepatitis, and more than one cause can be present at once.
How cirrhosis is diagnosed
Cirrhosis is usually suspected from medical history, physical examination, blood work, and imaging, and it is staged rather than simply confirmed, since how far the disease has progressed changes monitoring and treatment. Doctors commonly use two scoring systems, the MELD score, now updated to MELD 3.0, and the Child-Pugh classification, which combine routine liver blood work into a single measure of how well the liver is still functioning.
| Score | What it means |
|---|---|
| MELD score | Combines bilirubin, INR, and creatinine (sometimes sodium) into a number that predicts 90-day survival; higher scores mean higher priority for liver transplant |
| Child-Pugh class A (5-6 points) | Best prognosis; liver function is well compensated, with roughly 10 percent surgical mortality risk |
| Child-Pugh class B (7-9 points) | Moderately impaired function, with roughly 30 percent surgical mortality risk |
| Child-Pugh class C (10-15 points) | Severely impaired function, with 70 to 80 percent surgical mortality risk and the highest priority for transplant evaluation |
A common misconception is that healthy-looking liver enzymes rule out cirrhosis. Reviewing the ALT liver enzyme result and the AST liver enzyme result tells only part of the story: in advanced, burned-out cirrhosis, so little functioning tissue remains that both enzymes can be normal, so a normal ALT or AST does not rule out cirrhosis. Their relationship also matters: an AST:ALT ratio above 1, and especially above 2, points toward alcohol-related disease, while a ratio below 1 is more typical of MASLD, though the ratio tends to climb as cirrhosis advances regardless of cause. Checking the alkaline phosphatase level and the GGT level narrows the underlying cause further, since alkaline phosphatase rises more with bile-duct injury such as primary biliary cholangitis, while GGT rises more with heavy alcohol use.
Tracking the bilirubin level and the prothrombin time result shows how well the liver is still clearing waste and making clotting proteins, and calculating the standardized INR value, together with albumin, feeds directly into the MELD and Child-Pugh scores above. Watching the platelet count over time offers another clue: as scar tissue raises pressure in the portal vein, the spleen enlarges and traps platelets, so a falling count often signals advancing fibrosis before other numbers change. Doctors can also calculate the FIB-4 index from age, AST, ALT, and platelet count: 1.30 or below makes advanced fibrosis unlikely, 2.67 or above flags high risk, and anything between calls for further testing such as transient elastography, or FibroScan, which measures liver stiffness noninvasively and has reduced how often a liver biopsy is needed. Because cirrhosis substantially raises the risk of liver cancer, guidelines recommend surveillance every six months with an ultrasound and an AFP blood test for as long as cirrhosis is present, and understanding the liver cancer risk is part of long-term monitoring.
Treatment options for cirrhosis
No medication reverses established cirrhosis itself, but treatment can still change its course substantially. The first priority is addressing the underlying cause: stopping alcohol use completely, starting antiviral medication for hepatitis B or C, or managing the metabolic conditions that drive MASH. Each complication then has its own specific treatment.
| Approach | Role |
|---|---|
| Treating the underlying cause | Antivirals for hepatitis B or C, complete alcohol avoidance, and metabolic management for MASH slow or halt progression |
| Beta blockers and band ligation | Lower pressure in the portal vein and treat enlarged veins, or varices, to help prevent dangerous bleeding |
| Diuretics and salt restriction | Reduce fluid buildup in the abdomen (ascites) and swelling in the legs |
| Lactulose and rifaximin | Lower ammonia-producing gut bacteria to treat and prevent confusion from hepatic encephalopathy |
| Vaccination | Protects against hepatitis A and B, pneumococcal disease, shingles, influenza, and COVID-19, all riskier with liver disease |
| Nutrition support | Adequate protein and calories help prevent muscle wasting and support liver function |
| Liver transplant | The only definitive treatment once cirrhosis reaches end-stage, decompensated disease |
Because the liver has real, if limited, capacity to heal, catching damage before it becomes true cirrhosis matters enormously: earlier-stage fibrosis often improves, and sometimes reverses, once the underlying cause is treated, such as through sustained alcohol abstinence, curing hepatitis C, or meaningful weight loss with MASH. Once cirrhosis is established, the scarring is largely permanent, so the goal shifts to preventing further damage and catching complications early. Anyone with cirrhosis should avoid alcohol completely and check with a clinician before starting any new medication or supplement, since many drugs are processed by the liver.
Living with cirrhosis and long-term outlook
Outlook depends heavily on which stage a person is in. Compensated cirrhosis can remain stable for years, and many people continue working, traveling, and living full lives with routine monitoring. Decompensated cirrhosis is more serious: life expectancy narrows once complications such as ascites, variceal bleeding, or confusion appear, usually prompting formal evaluation for a liver transplant. This is why the compensated-versus-decompensated distinction introduced earlier matters in day-to-day life, not just on a lab report.
Living well with cirrhosis means steady follow-up: repeat blood work and imaging to track the MELD or Child-Pugh trend, periodic endoscopy to check for varices, and twice-yearly liver cancer screening for as long as cirrhosis is present. Daily choices matter too, including adequate dietary protein, salt restriction if ascites develops, avoiding alcohol and nonprescription anti-inflammatory drugs, and staying current on vaccines. With consistent care, many people with compensated cirrhosis avoid decompensation for a long time, and even after decompensation, treatment and transplant can extend and improve life.
Latest scientific advances in cirrhosis research
Recent research has focused on treating the metabolic liver disease that increasingly drives cirrhosis in the United States. According to PubMed-indexed research, a phase 3 trial of resmetirom in patients with biopsy-confirmed MASH and liver fibrosis found that the drug resolved liver inflammation without worsening fibrosis in roughly a quarter to nearly a third of treated patients, compared with about 1 in 10 on placebo, leading to its accelerated FDA approval as the first medication for MASH (Harrison et al., 2024). What this means for you: there is now an approved drug aimed directly at slowing the liver damage that can lead to cirrhosis, rather than relying on weight loss alone. A related trial found that semaglutide, a GLP-1 medication already widely used for diabetes and weight management, resolved steatohepatitis without worsening fibrosis in about 63 percent of MASH patients with significant fibrosis, compared with about 34 percent on placebo (Sanyal et al., 2025). What this means for you: a medication many people already take for other metabolic conditions may also help reverse early liver damage, tying liver health closely to weight and blood sugar control.
Other research has focused on preventing complications once cirrhosis is present. A 2024 multicenter study comparing beta blockers found that carvedilol reduced the risk of a first decompensation event in compensated cirrhosis by about 39 percent, and reduced further decompensation or death in decompensated cirrhosis by about 43 percent, compared with older nonselective beta blockers such as propranolol (Fortea et al., 2024). What this means for you: if a beta blocker is recommended for variceal bleeding, carvedilol has evidence of benefit at more than one stage of cirrhosis, worth discussing if you take an older alternative.
Glossary of key cirrhosis terms
| Term | Definition |
|---|---|
| Compensated cirrhosis | Cirrhosis in which the liver still performs most of its normal functions, often with few or no symptoms. |
| Decompensated cirrhosis | Cirrhosis in which the liver can no longer keep up, leading to complications such as ascites, bleeding, or confusion. |
| Portal hypertension | Elevated pressure in the portal vein caused by scarring, which drives many cirrhosis complications. |
| Varices | Enlarged, fragile veins, most often in the esophagus, that can bleed suddenly and seriously. |
| Ascites | Fluid buildup in the abdomen caused by portal hypertension and low albumin. |
| Hepatic encephalopathy | Confusion or personality changes caused by toxins the liver can no longer clear effectively. |
| MASLD and MASH | Metabolic dysfunction-associated steatotic liver disease and its more severe form, renamed from NAFLD and NASH in 2023. |
Frequently asked questions about cirrhosis
Is cirrhosis of the liver reversible?
Established cirrhosis is generally considered permanent, since dense scar tissue does not fully clear once it replaces healthy tissue. Earlier-stage fibrosis, before true cirrhosis develops, can improve or even reverse when the underlying cause is treated, such as through alcohol abstinence, curing hepatitis C, or losing weight with MASH.
What is the difference between compensated and decompensated cirrhosis?
Compensated cirrhosis means the liver still performs most of its normal functions, and many people have few or no symptoms. Decompensated cirrhosis means the liver can no longer keep up, leading to complications such as ascites, variceal bleeding, jaundice, or confusion. This distinction is the biggest factor in how cirrhosis is monitored and treated.
What causes cirrhosis besides alcohol?
Alcohol is only one cause. MASLD and its more severe form, MASH, chronic hepatitis B and hepatitis C, autoimmune hepatitis, hereditary hemochromatosis, and primary biliary cholangitis can all lead to cirrhosis. More than one cause can be present at once.
What are the early signs and symptoms of cirrhosis?
Early, compensated cirrhosis often causes no symptoms. When signs do appear, they tend to be subtle: fatigue, loss of appetite, easy bruising or bleeding, itchy skin, mild jaundice, and small spider-like blood vessels on the skin. These signs are easy to attribute to other causes, so cirrhosis sometimes goes unnoticed until routine blood work or imaging finds it.
How is cirrhosis diagnosed without a biopsy?
Biopsy is no longer always necessary. Doctors can combine blood tests such as the FIB-4 index, using age, AST, ALT, and platelet count, with imaging tests such as transient elastography or MRI elastography, which measure liver stiffness directly. Together these noninvasive tools can confirm advanced fibrosis or cirrhosis without a biopsy, now reserved mainly for unclear cases.
Can you live a long life with cirrhosis if you stop drinking?
Yes, many people do. Stopping alcohol completely is one of the most powerful steps someone with cirrhosis can take, and it can halt or slow progression, reduce the risk of decompensation, and improve survival, especially while still compensated. Combined with regular monitoring and prompt treatment of complications, many people who stop drinking remain stable for years.
Sources
- National Institute of Diabetes and Digestive and Kidney Diseases — Cirrhosis — NIDDK, 2024 — niddk.nih.gov
- Mayo Clinic — Cirrhosis: Diagnosis and Treatment — Mayo Clinic, 2024 — mayoclinic.org
- American Association for the Study of Liver Diseases — Why Do We Use the Model for End-Stage Liver Disease (MELD) Score? — AASLD Liver Fellow Network, 2023 — aasld.org
- Harrison et al. — A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis — New England Journal of Medicine, 2024 — doi.org/10.1056/NEJMoa2309000
- Sanyal et al. — Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis — New England Journal of Medicine, 2025 — doi.org/10.1056/NEJMoa2413258
- Fortea et al. — Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis — Journal of Hepatology, 2024 — doi.org/10.1016/j.jhep.2024.12.017
Further reading
- Learn about a related marker in this guide to the direct bilirubin test.
- See how technology is changing test interpretation in this guide to a rising liver enzyme result.
- Build confidence reading test results with this guide to reference ranges, flags, and next steps on a lab report.
Understand your lab results with BloodSense
Cirrhosis care rarely comes down to one number. ALT, AST, alkaline phosphatase, GGT, bilirubin, albumin, prothrombin time, INR, and platelet count each capture a different piece of how the liver is working, from active inflammation to synthetic function to portal pressure, and doctors combine several into scores like MELD and Child-Pugh to judge how advanced the disease is. Seeing where each value sits against its reference range, and how it trends over time, makes these results easier to act on with your care team.
